Format

Send to

Choose Destination
Klin Monbl Augenheilkd. 2018 May;235(5):562-567. doi: 10.1055/a-0586-3931. Epub 2018 May 8.

[Conventional Synthetic Disease-modifying Antirheumatic Drugs (DMARDs) for the Treatment of Non-infectious Uveitis].

[Article in German; Abstract available in German from the publisher]

Author information

1
Universitätsklinik für Augenheilkunde, Inselspital, Bern, Schweiz.
2
1. Medizinische Klinik, St. Franziskus-Hospital, Münster.
3
Augenabteilung, St. Franziskus-Hospital, Münster.

Abstract

in English, German

The first-line therapy of uveitis normally consists of topical and/or systemic corticosteroid use. To achieve long-term ocular quiescence, to prevent uveitic secondary complications, to allow corticosteroid sparing and to avoid corticosteroid-related adverse effects, the application of immunosuppressive drugs (disease modifying antirheumatic drugs; DMARDs) is often necessary during the course of the disease. This article presents a structural overview of the most important conventional synthetic DMARDs, their indication, adverse events and interdisciplinary monitoring.

PMID:
29739025
DOI:
10.1055/a-0586-3931

Conflict of interest statement

CT nein, TR nein, AH Institutionell: BMBF, DFG; nicht institutionell: AbbVie, Alimera, Sciences, Allergan, MSD, Pfizer, Santen, Xoma.

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center